Background: Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG),
Discussion:
The high acceptability and feasibility of screening and treatment of CT, NG, and TV among pregnant women supports further research to evaluate the cost-effectiveness of prenatal CT, NG, and TV screening programs.
E very year, there are an estimated 349 million new infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) globally. 1 In pregnant women, those infections can be linked to serious adverse birth outcomes, including premature labor, premature birth, and low-birth-weight infants. [2] [3] [4] Furthermore, maternal CT or NG infection during birth can cause mother-to-child CT or NG transmission in 30% to 70% of cases. [5] [6] [7] Neonatal CT infection can cause chlamydial opthalmia neonatorum and chlamydial pneumonia. Neonatal NG infection can cause gonococcal opthalmia neonatorum, which, if untreated, may lead to blindness. Finally, maternal infection with CT, NG, or TV may be associated with an increased chance of acquiring HIV infection and an increased likelihood of mother-tochild HIV transmission. 8, 9 Currently, maternal diagnostic screening for CT, NG, and TV is only done in a limited number of countries. 10 Diagnostic screening typically involves nucleic acid amplification tests that are expensive and take multiple days to receive results. Because of the limited access to laboratory testing and the lack of costeffectiveness data, the World Health Organization (WHO) only recommends symptom-based management of CT, NG, and TV. 11 However, because most of those infections are asymptomatic, the syndromic management approach leaves many sexually transmitted diseases (STDs) undiagnosed and untreated, and thus may contribute to a large number of attributable adverse birth outcomes. A recent study in Australia showed that prenatal CT screening and treatment reduced the risk of adverse birth outcomes on a population level. 12, 13 Many rapid diagnostic tests for CT, NG, and TVare in development or newly available.
14 Such tests will increase the accessibility of prenatal STD screening globally by increasing access to testing. However, STD screening is often viewed as stigmatizing, and specimen collection through pelvic examination or self-collected vaginal swabs might be considered invasive. 15 As rapid diagnostic tests become more readily available, it is critical to evaluate the acceptability and feasibility of prenatal screening programs for CT, NG, and TV. Measuring the acceptability and feasibility is a key step in informing the development of policy recommendations.
The WHO defines acceptability as the extent to which an intervention is considered to be reasonable among those receiving, delivering, or affected by the intervention. Feasibility is defined as the likelihood that an intervention can be properly carried out or implemented in a given context. 16 Studies have shown prenatal syphilis screening to be acceptable and feasible. 17, 18 A study done in Australia used qualitative methods to assess acceptability of rapid CT and NG testing among primary care providers in remote settings. 19 The study found high acceptability of testing among primary care providers delivering the intervention. In this study, we aimed to evaluate the acceptability and feasibility of prenatal CT, NG, and TV screening and treatment among pregnant women in low-to middle-income countries. To do this, we compiled acceptability and feasibility data from CT, NG, and TV screening and treatment projects conducted by our study team in 6 different lowto middle-income countries.
MATERIALS AND METHODS
Over the past 5 years, we have conducted STD screening studies among pregnant women in 6 distinct settings. A total of 1817 pregnant women were recruited for CT, NG, and TV screening at prenatal clinics in Botswana, the Democratic Republic of Congo (DRC), Haiti, South Africa, and Vietnam. [20] [21] [22] In addition, 640 pregnant women were recruited for CT screening at prenatal clinics in Peru. 23 In Botswana, DRC, Haiti, South Africa, and Vietnam, eligible women were pregnant, 18 years or older, and less than 35 weeks pregnant. Eligible women in Peru were 16 years or older and less than 41 weeks pregnant. Samples were obtained via self-collected vaginal swabs in Botswana, Haiti, Peru, South Africa, and Vietnam. In DRC, vaginal swabs were collected by the physician during the prenatal visit. Testing in Botswana, DRC, Haiti, South Africa, and Vietnam was conducted using the GeneXpert CT/NG and TV tests (Cepheid, Sunnyvale, CA). In Peru, testing was done using the Aptima Combo2 system (Hologic, San Diego, CA). Study protocols were approved by incountry institutional review boards/research ethics committees and the University of California, Los Angeles, as well as local health departments and participating hospitals.
Women who tested positive for an STD were treated with 1 g of oral azithromycin for CT infection, with 250 mg injection of ceftriaxone plus 1 g of oral azithromycin for NG infection, or with 2 g of oral metronidazole for TV infection. However, in DRC, women with NG infection were treated with 1 g of oral azithromycin without ceftriaxone, per local guidelines. For HIVinfected participants with TV infection, the dosage of metronidazole was 400 mg orally twice daily for 7 days. Patients were asked to return to the clinic in 3 to 6 weeks for a test of cure. Women typically received same-day treatment in South Africa and Botswana, whereas patients returned to the clinic for treatment in Haiti, DRC, Peru, and Vietnam. Women who tested positive for CT, NG, or TV were given antibiotics to bring to their partner or asked to bring their partner in for treatment.
We assessed acceptability of screening by measuring the uptake of screening among eligible pregnant women. We measured feasibility of treatment by measuring the proportion of pregnant women who tested positive that received treatment. We calculated 95% confidence intervals for acceptability of screening and feasibility of treatment using the binomial method. We calculated percent acceptability overall weighted by the sample size. We also used a full Bayesian method for bivariate random-effects metaanalysis to calculate pooled estimates of acceptability of screening and feasibility of treatment with SAS (v9.4; Cary, NC) PROC MCMC. 24 By using quantitative metrics, we were able to compare results between countries and determine overall acceptability and feasibility of prenatal CT, NG, and TV screening and treatment among the 6 sample populations.
RESULTS
Acceptability of CT, NG, and TV screening among pregnant women was consistently high, with values ranging from 85% to 99%. Feasibility of treatment was also high, ranging from 91% to 100%. Specific values for the acceptability of screening and feasibility of treatment are shown in the Table 1 .
DISCUSSION
Prenatal CT, NG, and TV screening and treatment was acceptable and feasible among pregnant women across all 6 study populations. Despite the stigma associated with STD testing, nearly all pregnant women were willing to participate in screening, and nearly all who tested positive successfully received treatment. The high acceptability of screening and treatment among pregnant women, in conjunction with previously found high acceptability among primary care providers, indicates an overall high acceptability of prenatal screening programs for CT, NG, and TV among various populations. 19 Furthermore, the successful treatment of prenatal STDs across multiple settings indicates the feasibility of identifying and treating prenatal STDs in countries that traditionally rely on syndromic management. Those findings should be used to inform the development of screening policies for STDs in pregnancy.
We evaluated acceptability and feasibility of CT, NG, and TV screening and treatment using quantitative measures: uptake of screening and the proportion of women who tested positive that received treatment. By using those measures, we were able to quantitatively compare results by country, specimen collection method, and treatment practice. We were also able to avoid response biases that can occur with interviews or surveys.
Despite such advantages, our method of evaluation had a few limitations. Most notably, we have limited information on specific reasons for accepting or declining screening or treatment. In the Botswana, Peru, and DRC studies, the primary reason for nonacceptance of screening was lack of time. It was rare that testing was refused because of screening methods. 20, 21 However, without qualitative measures at every site, we cannot infer why different sites had varying levels of acceptability and feasibility, and we cannot determine how acceptability and feasibility might be improved. Notably, acceptability of screening was lowest in DRC, which was the only site that used physician-collected vaginal swabs instead of self-collected samples. In addition, feasibility of treatment was slightly higher at sites that provided same-day treatment than sites that did not, likely due to the fact that patients did not have to return to clinic to receive treatment.
Another limitation stems from the fact that, although each country had very similar protocols, there were differences from site to site, ranging from differences in staff to differences in clinic set-up. It is possible that such differences may have influenced acceptability and feasibility rates from site to site. However, those differences also reflect the reality of implementing STD screening and treatment programs in diverse real-world settings, and support the generalizability of our findings.
Finally, data were only collected from 1 or 2 clinical settings per country. The results do not reflect the acceptability and feasibility in entire regions or countries, and may not reflect all socioeconomic or demographic groups.
Moving forward, well-powered trials to evaluate the effectiveness of prenatal CT, NG, and TV screening programs to prevent adverse birth outcomes are urgently needed. It is also essential to evaluate other aspects of feasibility, such as outcomes of partner treatment, cure rates, and rates of reinfection. Ultimately, program sustainability will depend on updating WHO guidelines and adoption on the country level.
Understanding the acceptability and feasibility of prenatal STD screening in low-to middle-income country settings is an important step toward implementing such programs. The high acceptability of screening and feasibility of treatment suggest that women are willing to provide self-collected vaginal swabs, undergo screening, and receive treatment. Given the increasing accessibility of rapid diagnostic STD tests and the high acceptability and feasibility of screening and treatment, the data support further programmatic evaluation of prenatal CT, NG, and TV screening programs.
